Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Journal Volume
78
Journal Issue
5
Start Page
1295
End Page
1303
ISSN
1537-6591
Date Issued
2024-05-15
Author(s)
Yang, Chia-Jui
Lu, Po-Liang
Lee, Yuan-Ti
Lee, Nan-Yao
Liou, Bo-Huang
Tang, Hung-Jen
Lee, Mei-Hui
Wang, Ning-Chi
Chen, Tun-Chieh
Hii, Ing-Moi
Huang, Sung-Hsi
Lin, Chi-Ying
Tsai, Chin-Shiang
Cheng, Chien-Yu
Taiwan HIV Study Group
Abstract
Background. Real-world experience with combinations of short-course rifapentine-based regimens and integrase strandtransfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods. From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens. Results. During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate. Conclusions. Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.
Subjects
drug interaction
integrase strand-transfer inhibitor
interferon-gamma release assay
isoniazid
rifamycin
Type
journal article